Stock comparison
BOSTON SCIENTIFIC CORP is 35.2x more valuable than NovoCure Ltd by market capitalization ($66.54 B vs $1.89 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
BSX is larger
BOSTON SCIENTIFIC CORP is 35.2x more valuable than NovoCure Ltd by market capitalization ($66.54 B vs $1.89 B).
Market value leader
BSX
BOSTON SCIENTIFIC CORP is 35.2x more valuable than NovoCure Ltd by market capitalization ($66.54 B vs $1.89 B).
Revenue leader
BSX
NVCR: $655.35M vs BSX: $20.07B.
| Metric | NVCR | BSX |
|---|---|---|
| Market cap | $1.89 B | $66.54 B |
| US-listed rank | #2189 | #257 |
| Revenue (latest FY) | $655.35M | $20.07B |
| Net income (latest FY) | -$136.23M | - |
| Net margin | -20.8% | - |
| P/E (trailing FY) | - | - |
| SEC filings | 1,138 | 1,009 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
BOSTON SCIENTIFIC CORP is 35.2x more valuable than NovoCure Ltd by market capitalization ($66.54 B vs $1.89 B).
In their latest fiscal years, NovoCure Ltd reported $655.35M in revenue while BOSTON SCIENTIFIC CORP reported $20.07B.
Full pages: NovoCure Ltd and BOSTON SCIENTIFIC CORP, or browse the full rankings.